Mitochondrial-Derived Peptides: A Novel Class
Mitochondrial-derived peptides (MDPs) represent a relatively recently discovered class of bioactive molecules encoded within the mitochondrial genome. Unlike the nuclear genome, which encodes the vast majority of known proteins, the mitochondrial genome was long thought to encode only thirteen proteins, all components of the electron transport chain, along with ribosomal and transfer RNAs. The discovery that short open reading frames within mitochondrial DNA encode bioactive peptides has been documented as a paradigm shift in mitochondrial biology.
The first mitochondrial-derived peptide identified was humanin, discovered in 2001 through research on neuronal cell survival. Subsequent investigations revealed additional MDPs encoded within mitochondrial ribosomal RNA genes, expanding the known repertoire of mitochondrial-encoded bioactive molecules. This class of peptides has been documented in published literature as occupying a unique position at the intersection of mitochondrial genetics, cellular metabolism, and intercellular signaling.
The recognition that mitochondria — organelles with their own genome inherited exclusively through the maternal lineage — produce signaling peptides that can influence systemic physiology has been characterized in published reviews as opening new avenues for research into metabolic regulation, aging, and cellular stress responses.
Discovery of MOTS-C
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) was discovered in 2015 by Changhan Lee and colleagues at the University of Southern California. The discovery was published in Cell Metabolism, one of the leading journals in metabolic research. MOTS-C is a 16-amino acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded within the 12S ribosomal RNA gene of the mitochondrial genome.
The discovery of MOTS-C emerged from systematic analysis of potential short open reading frames within mitochondrial DNA sequences. Using bioinformatic approaches combined with mass spectrometry verification, the investigators confirmed that the MOTS-C peptide is endogenously produced and detectable in circulation. The 2015 Cell Metabolism publication documented that MOTS-C targets skeletal muscle and enhances glucose metabolism in experimental models.
This discovery has been noted in published literature as significant for several reasons. First, it demonstrated that the mitochondrial genome harbors functional genes beyond the traditionally recognized thirteen protein-coding genes. Second, it identified a mitochondrial-encoded peptide that acts as a systemic signaling molecule, circulating in the blood and influencing distant tissues. Third, it connected mitochondrial genetics directly to metabolic regulation in a manner that had not been previously appreciated.
Structure and Expression
MOTS-C is a 16-amino acid peptide with a molecular weight appropriate to its sequence. The peptide is produced through translation of a short open reading frame within the mitochondrial 12S rRNA gene. Unlike nuclear-encoded peptides that are translated on cytoplasmic ribosomes, MOTS-C is translated within mitochondria and subsequently exported to influence both intracellular and extracellular signaling.
Published research has documented that MOTS-C can be detected in multiple tissues and in circulating plasma. The peptide has been observed to translocate from mitochondria to the cell nucleus during periods of metabolic stress — a finding documented by Lee and colleagues that has been characterized as revealing a novel mitochondria-to-nucleus communication pathway.
The expression of MOTS-C has been documented as responsive to physiological stimuli. Research published in Nature Communications by Reynolds and colleagues in 2021 provided evidence that MOTS-C is an exercise-induced peptide, with levels rising in skeletal muscle and circulation following physical activity. This observation has positioned MOTS-C as a potential molecular mediator of exercise-related metabolic adaptations in the research literature.
Exercise-Induced Expression Research
The 2021 Nature Communications study by Reynolds and colleagues represents one of the landmark publications in MOTS-C research. The investigators demonstrated that MOTS-C significantly enhanced physical performance in young, middle-aged, and old mice. Notably, late-life treatment with MOTS-C increased physical capacity and markers associated with healthspan in aged mice.
The study documented that exercise considerably raises endogenous MOTS-C levels in skeletal muscle and circulation, establishing MOTS-C as an exercise-induced mitochondrial-encoded regulator. This finding has been cited extensively in subsequent literature as connecting mitochondrial peptide signaling to the documented physiological effects of physical activity.
Additional research published in the Diabetes and Metabolism Journal has documented that plasma MOTS-C levels decline with age in humans. This age-related decline has been observed to parallel decreases in mitochondrial function, metabolic efficiency, and physical capacity that have been documented in the aging literature. The temporal correlation between declining MOTS-C levels and age-associated metabolic changes has been noted as an area of active investigation.
Detailed research summaries and full citation information for MOTS-C are available on the MOTS-C research page.
The Folate-AICAR-AMPK Pathway
A 2023 review published in Frontiers in Physiology documented the proposed molecular mechanism through which MOTS-C exerts its metabolic effects. The pathway has been characterized as the Folate-AICAR-AMPK axis, representing a signaling cascade that connects mitochondrial peptide signaling to cellular energy sensing and gene expression regulation.
Research has documented that MOTS-C inhibits the folate cycle, leading to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). AICAR is a well-characterized activator of AMP-activated protein kinase (AMPK), a master regulator of cellular energy metabolism. AMPK activation has been extensively documented in published literature as stimulating glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while suppressing anabolic processes during periods of energy deficit.
During metabolic stress, MOTS-C has been observed to translocate to the nucleus, where it has been documented as regulating the expression of genes containing antioxidant response elements. This nuclear translocation represents a direct communication pathway from mitochondria to the nuclear genome, enabling mitochondrial metabolic status to influence nuclear gene expression programs.
The Folate-AICAR-AMPK pathway described for MOTS-C has been noted in published reviews as providing a mechanistic framework for understanding how a mitochondrial-derived peptide could influence systemic metabolic parameters including glucose homeostasis, insulin sensitivity, and cellular stress resistance.
Age-Related Decline and Metabolic Research
The documented decline of circulating MOTS-C levels with age has been characterized as consistent with the broader phenomenon of mitochondrial functional decline during aging. Published research has documented that mitochondrial DNA copy number, electron transport chain efficiency, and mitochondrial membrane potential all decrease with advancing age across multiple species studied.
Research in the original 2015 Cell Metabolism publication documented that MOTS-C administration prevented age-dependent and high-fat-diet-induced insulin resistance in mouse models. These observations, combined with the exercise-induction data and age-related decline findings, have been compiled in published reviews as suggesting that MOTS-C may function as a mitochondrial-derived signal linking physical activity, metabolic status, and aging processes.
MOTS-C is available as part of the Metabolic Stack alongside Retatrutide, organized for researchers investigating metabolic signaling pathways. Individual vials are available through the singles catalog for custom research protocols. Additional compound information and research summaries are accessible through the Hot Peps research hub.
Research Compliance Disclaimer
All information presented in this article reflects outcomes and observations reported in published research studies. MOTS-C is sold strictly for in vitro research, laboratory use, and scientific investigation only. It is not intended for human consumption, veterinary use, or any diagnostic or therapeutic application. No information in this article constitutes medical advice or therapeutic guidance.